Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Biotechnology

Healthcare
$3.99 -0.81%

-$0.04 today

Market cap
$320.41M
Beta
0.32
P/E (TTM)
-2.0
EPS (TTM)
-$2.14
52W Low $2.78High $6.45

Volume 0.34M

Average 0.34M

AVIR Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Atea Pharmaceuticals, Inc.NASDAQ: AVIR

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt remains negative

Q1 FY2026 short-term debt was $634K, compared with $0 a year earlier.

Context

  • Short-term debt amounted to 0.2% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
  • Short-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$634K-24.8% QoQ
Last fiscal yearDec 2025
$843K— YoY
Year agoMar 2025
$0— since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
843K USD
Year-over-year change
—

Short-term Debt vs competitors

How AVIR compares with its peers on the latest reported figures

  • AVIR's Mar 2026 short-term debt of $634K is the 3rd highest of the 5 companies compared; the peer median is $4.47M.
  • Short-term debt amounts to 0.2% of total assets for AVIR, versus a peer median of 0.4%.
AVIR Competitors Peer median
Short-term Debt for AVIR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$35.22M +14.8%—11.2%
VIRVir Biotechnology, Inc.Mar 2026$8.94M ——0.9%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$634K ——0.2%
ABUSArbutus Biopharma CorporationMar 2026$0 —+13.7%0.0%
ASMBAssembly Biosciences, Inc.Mar 2026$0 ——0.0%
Peer median (excluding AVIR) $4.47M+14.8%+13.7%0.4%

Competitors are the stored peer set for AVIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents764.38M646.71M143.82M64.7M95.71M
Short-term Investments00434.28M390.03M206.12M
Net Receivables00000
Inventory00000
Other Current Assets(0)14.21M12.35M7.63M9.16M
Total Current Assets772.4M660.92M590.46M462.36M310.99M
Property, Plant & Equipment (Net)184K4.09M3.12M2.12M1.09M
Goodwill00000
Intangible Assets00000
Long-term Investments305K198K000
Tax Assets00000
Other Non-current Assets01.49M1.4M197K3.14M
Total Non-current Assets489K5.79M4.51M2.31M4.23M
Total Assets772.89M666.71M594.97M464.67M315.22M
Account Payables4.53M2.55M4.25M4.46M12.95M
Short-term Debt0000843K
Tax Payables099K000
Deferred Revenue00000
Other Current Liabilities27.57M8.65M07.44M19.56M
Total Current Liabilities56.88M18.48M32.38M18.6M39.78M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities5.93M5.26M5.76M6.36M0
Total Non-current Liabilities5.93M7.66M7.4M7.2M0
Total Liabilities62.82M26.14M39.78M25.8M39.78M
Common Stock83K83K83K84K78K
Retained Earnings56.03M(59.88M)(195.84M)(364.22M)(522.57M)
Accumulated OCI(0)(684K)207K233K174K
Other Stockholders Equity00000
Minority Interest00000
Total Equity710.08M640.57M555.19M438.87M275.43M
Total Debt197K3.12M2.4M1.64M843K
Net Debt(764.18M)(643.59M)(141.42M)(63.05M)(94.87M)

Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.